Aspire Biopharma Completes SPAC Merger and Patent Filings
By ATTN Desk · Editorial oversight: Sean Han
ASPIRE BIOPHARMA HOLDINGS INC (Ticker: ASBP)
Introduction
ASPIRE BIOPHARMA HOLDINGS INC is an early-stage biopharmaceutical company headquartered in Humacao, Puerto Rico. The company develops patent-protected sublingual delivery mechanisms aimed at rapid absorption of drugs and supplements. Its technology utilizes a novel soluble formulation to bypass the gastrointestinal tract and deliver high-dose treatments directly into the bloodstream.
Corporate Structure and Team
- Founding: Formed in September 2021 through a merger with PowerUp Acquisition Corp.
- Headcount: Approximately 51–200 employees (LinkedIn data).
- Leadership:
- Kraig Higginson, Chief Executive Officer
- Senior hires include a Chief Commercial Officer and a Head of Regulatory Affairs with experience in European regulatory environments.
- Manufacturing & Quality: Roles such as Quality Control Senior Chemist require a BS in Chemistry and at least eight years of pharmaceutical experience.
Recent Developments and News
- September 3, 2024: Announcement of a business combination agreement, valuing Aspire at a pre-money equity value of approximately $316 million.
- October 2, 2024: Filing of a second patent application (US application 63/702,381) for high-dose aspirin micelle-based technology.
- January 31, 2025: Stockholder approval for the SPAC merger with PowerUp Acquisition Corp.
- February 17, 2025: Closing of the business combination, with the company renamed Aspire Biopharma Holdings, Inc.
- February 20, 2025: Trading commenced on the Nasdaq Global Market under ticker “ASBP” (common stock) and “ASBPW” (warrants).
- March 20, 2025: Completion of the first GMP clinical batch of the oral mucosal fast-acting aspirin formulation by contract manufacturer Glatt Air Techniques.
- April 2025: Initiation of a bioavailability study in healthy volunteers.
- Q2 2025: Planned final clinical trial comparing sublingual aspirin pharmacodynamics with standard oral aspirin, targeting “fast track” FDA designation.
Financial and Strategic Analysis
| Metric | Value | Date/Period |
|---|---|---|
| Share Price | $0.3816 (+60.67%) | As of 2025-05-28 |
| Daily Volume | 53,731,071 shares | As of 2025-05-28 |
| Market Capitalization | $11.76 million | Intraday, per Yahoo Finance |
| Net Income (TTM) | -$17.02 million | Trailing twelve months |
| Diluted EPS (TTM) | -$0.58 | Trailing twelve months |
| Total Cash (MRQ) | $1.35 million | Most recent quarter |
| Beneficial Ownership (Lance Friedman) | 2,207,886 shares (4.52%) | Schedule 13G/A filed 2025-05-19 |
- R&D Investment: Focuses on sublingual aspirin for cardiology emergencies and pain management.
- Patent Portfolio: Two key filings (March 2023 and October 2024) support rapid-absorption formulations.
- Capital Access: The SPAC merger is expected to provide proceeds to advance clinical programs and increase manufacturing scale.
- Liquidity Position: $1.35 million in cash against ongoing R&D expenses, indicating potential need for additional financing to sustain operations beyond initial clinical phases.
Market Position and Industry Context
- Therapeutic Focus: Targets FDA-approved drugs, nutraceuticals, and supplements; sublingual delivery mechanisms are aimed at addressing opioid crisis-related issues, erectile dysfunction, traumatic brain injury, and emergency cardiac care.
- Competitive Edge: Aspire's technology aims for rapid onset of action and high-dose capability, differentiating its platform from conventional oral tablets.
- Industry Trends: There is increasing interest in non-invasive delivery systems, nano-formulations, and rapid-acting emergency treatments.
- Peers and Comparables: Operates within a framework of early-stage biotechnologies typically characterized by market capitalizations under $100 million, pending clinical data advancements.
TL;DR
Aspire Biopharma began trading on February 20, 2025, with shares priced at $0.3816 (up 60.67%) as of May 28, 2025, with 53.7 million shares traded. The company completed its SPAC merger on February 17, 2025, and holds two key patents filed in March 2023 and October 2024. On March 20, 2025, its contract manufacturer completed the first GMP clinical batch of aspirin. A bioavailability study commenced in April 2025, with a pharmacodynamic trial scheduled for Q2 2025 along with plans for FDA fast-track status. Future clinical developments and potential financing are expected to influence near-term outlook.